Part-Time

Supplemental Advanced Practice Provider

MHMG Primary Care

Memorial Hermann

Memorial Hermann

10,001+ employees

Integrated health system delivering patient-centered care

No salary listed

United States

In Person

Master's

Category
Medical, Clinical & Veterinary (1)
Required Skills
Patient Education

Get referred to Memorial Hermann

See people who can refer or advise you

Requirements
  • Graduate of a Nurse Practitioner program approved by the State of Texas and hold a master's degree.
  • Graduate of a nationally accredited Physician Assistant program.
  • Be licensed to practice professional nursing by the State of Texas, when applying through the Nurse Practitioner or Advanced Practice Nurse pathway.
  • Hold licensure as a Texas Advanced Practice Registered Nurse and be eligible for full prescriptive authority, when applying through the Nurse Practitioner or Advanced Practice Nurse pathway.
  • Be certified by a recognized national certification recognized by the Texas State Board in the relevant population focus or additional specialty area, when applying through the Nurse Practitioner or Advanced Practice Nurse pathway.
  • Be eligible for Drug Enforcement Administration licensure.
  • Hold Basic Cardiac Life Support or Advanced Cardiac Life Support certification.
  • Be certified by the National Commission on Certification of Physician Assistants, when applying through the Physician Assistant pathway.
  • Be licensed by the Texas State Board of Physician Assistant Examiners, when applying through the Physician Assistant pathway.
Responsibilities
  • Provide health promotion and assess, diagnose, and manage patient problems, including pharmacologic and non-pharmacologic interventions, assessment, triage, and therapeutic management of patient and family needs throughout the disease process and across the health wellness-illness continuum as part of an interdisciplinary team.
  • Act under the delegation of a supervising physician for prescriptive authority and maintain an active Prescriptive Authority Agreement in accordance with regulations and policy.
  • Practice within approved protocols, guidelines, clinical pathways, and evidence-based medicine.
  • Obtain medical histories; perform physical examinations; review, order, and interpret diagnostic tests and radiographic results; formulate and manage patient treatment plans and outcomes; and provide interventions and procedures within the legal scope and delegated authority, including incision and drainage, pelvic examinations, lesion removal or destruction, suturing, and casting or splinting.
  • Collaborate in the development and evaluation of patient care.
  • Update clinical guidelines, protocols, and pathways; work autonomously; accept accountability for outcomes; sign orders in accordance with institutional and state board requirements; collaborate in research and teaching projects; and apply research to practice.
  • Educate patients and families about care resources using interpersonal and verbal communication skills.
  • Participate in process improvement and multidisciplinary clinical outcome improvement activities using advanced nursing expertise.
  • Ensure safe care for patients, staff, and visitors and adhere to Memorial Hermann policies, procedures, standards, budgetary specifications, time-management requirements, supply-management requirements, productivity standards, and quality-of-service standards.
  • Maintain mandatory and continuing education and skills competency requirements, support department-based goals, and serve as a preceptor, mentor, and resource to less experienced staff.
  • Create compassionate and personalized experiences for every member of the community and model Memorial Hermann service standards by providing safe, caring, personalized, and efficient experiences to patients and colleagues.
  • Perform other duties as assigned.
Desired Qualifications
  • Two years of clinical experience preferred in the area of intended practice.
  • A master's degree is strongly preferred for the Physician Assistant pathway.

Memorial Hermann Health System is a nonprofit, community-owned health system serving the Greater Houston area with more than 260 care delivery sites. It delivers safe, high-quality, patient-centered care through an integrated network that combines clinical expertise with advanced technology. The system differentiates itself through its community ownership, value-driven culture, and broad network of hospitals, clinics, and specialty services. Its goal is to improve regional health outcomes by providing comprehensive, accessible care and leveraging innovation to personalize treatment.

Company Size

10,001+

Company Stage

Grant

Total Funding

$5M

Headquarters

Houston, Texas

Founded

1907

Get referred to Memorial Hermann

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • June 16, 2026 Helix Genomic Advantage gives employees clinical genomic screening and targeted care.
  • June 2026 Texas funded Memorial Hermann $750,000 to add a second mobile stroke unit.
  • HEAL High School reopened August 2026 with simulated hospital training and paid apprenticeships.

What critics are saying

  • Memorial Hermann will terminate commercial health plans by end-2027 after solvency concerns.
  • Federal prosecutors indicted transplant director John Bynon in February 2026; families still sue.
  • The September 2025 hidden-camera class action threatens reputation and trial expenses in 2026.

What makes Memorial Hermann unique

  • Memorial Hermann pioneered America’s first mobile stroke unit in 2014, now expanding it in 2026.
  • TIRR Memorial Hermann ranked No. 1 Texas rehabilitation hospital in 2026-2027 U.S. News.
  • GenoME and Helix Genomic Advantage embed population genomics into workforce care and research.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Professional Development Budget

Wellness Program

Mental Health Support

Growth & Insights and Company News

Headcount

6 month growth

14%

1 year growth

14%

2 year growth

14%
The Business Journals
Aug 19th, 2026
Former Houston transplant surgeon's federal case moves toward trial.

Former Houston transplant surgeon's federal case moves toward trial. By Megan Reyna - KHOU 11 Aug 19, 2026 Preview this article 1 min Dr. John Stevenson Bynon, 66, the former surgical director of liver transplantation at Memorial Hermann, is accused of falsifying medical records. Don't Stop Here - Continue Reading For $1 Per Week Secure 4 weeks of award-winning news and trusted insights Subscribe for only $4

AllSci
Jul 8th, 2026
Helix secures AstraZeneca partnership to power drug discovery with US genomic data.

Helix secures AstraZeneca partnership to power drug discovery with US genomic data. July 8, 2026 AstraZeneca has signed a multi-year agreement with San Mateo-based Helix to access its GenoSphere clinico-genomic cohort platform for drug discovery and development, adding a major US commercial data source to its existing population genomics infrastructure. The deal gives AstraZeneca (Nasdaq: AZN) access to Helix's continuously growing, deeply phenotyped cohorts spanning cardiometabolic, respiratory, and autoimmune disease areas. The agreement is AstraZeneca's latest move in a systematic multi-source genomics strategy and arrives as Helix establishes itself as a recurring platform partner to top-tier pharma. Financial terms were not disclosed. GenoSphere cohorts combine Exome+ genomic sequencing with longitudinal electronic health record data averaging 13 years of follow-up per patient, drawn from the Helix Research Network - described by the company as the largest precision health network in North America. The datasets are de-identified and fully consented, with the option to launch targeted follow-on studies. The platform is designed to support target identification, disease biology research, and patient stratification across the drug development lifecycle, functioning as a discovery infrastructure layer rather than a single-indication tool. Helix recently launched its Genomic Advantage program with Nebraska Medicine and Memorial Hermann Health System, adding new health system partners that feed the underlying research network. For AstraZeneca, the Helix deal adds a commercially managed, US-based, exome-sequenced cohort to a genomics portfolio that already includes co-funded access to the UK Biobank whole-genome sequencing dataset and membership in the Alliance for Genomic Discovery - a consortium that includes AbbVie, Amgen, GSK, Merck, and Novo Nordisk, among others. AstraZeneca's Centre for Genomics Research has publicly stated a goal of analyzing 2 million genomes by 2026. The Helix agreement adds a North American commercial data layer to AstraZeneca's existing European biobank partnerships. Helix previously signed a multi-year collaboration with GSK, announced in January 2026 using an identical structural template, with AstraZeneca now the third major pharma to sign onto the same GenoSphere platform following Helix's March 2026 agreement with Alnylam Pharmaceuticals. This article was generated with AI assistance and reviewed and edited by the AllSci editorial team Explore more at AllSci News: https://allsci.com/news/

Business Wire
Jun 23rd, 2026
Cadence Raises $100M Series C Led by Spark Capital to Automate Chronic Care

Cadence, the clinical AI company managing chronic care for older adults, announced a $100 million Series C, amid adoption of its AI-powered care model across...

PR Newswire
Jun 16th, 2026
Two US health systems launch Helix Genomic Advantage to cut costs through precision medicine

Nebraska Medicine and Memorial Hermann Health System have launched Helix Genomic Advantage, integrating clinical-grade genomic insights into care delivery for their workforces. The programme follows a similar launch with St. Luke's University Health Network. Both health systems are Helix Research Network partners operating large-scale community genomics studies. The Genomic Advantage model aims to implement precision medicine for targeted populations whilst reducing costs, addressing the high expense that has historically prevented scaling diagnostic genomics. "The high cost of diagnostic genomics has served as a significant barrier, preventing health systems from scaling these insights for patient populations," said James Lu, Helix CEO and co-founder. The programme aligns incentives to drive expanded access and total cost of care reduction across risk-based populations.

McIlroy Insurance Group
Jun 16th, 2026
Memorial Hermann Is Leaving the Houston Market. Here's What Every Business Owner and HR Manager Needs to Know

Memorial Hermann Is Leaving the Houston Market. Here's What Every Business Owner and HR Manager Needs to Know